ANZCTR search results

The primary purpose of this investigation is to determine the safety of the remote care paradigm where we evaluate if a clinician can reasonably assess a patient’s Parkinson’s Disease symptoms and adjust their therapy over a mobile platform. We hypothesize that this is safe mode of adjusting therapy.

The ACTIVate Study is a joint project between the University of South Australia, the University of Newcastle, the University of Adelaide, Flinders University and the University of Illinois. Our aim is to investigate the effect of different lifestyle patterns on brain function in older adults. Specifically, we're interested in activity and diet compositions, and how these might influence our risk of developing dementia. Four hundred and fifty participants will be recruited in Adelaide and Newcastle and followed over 3 years to monitor changes in lifestyle factors, brain structure and function, and overall health. From the information we collect we will develop a tool that will enable older adults to tailor their ‘best day’ of activity and diet compositions to reduce dementia risk.

This research aims to identify modifiable hospital, GP and family factors associated with asthma re-admissions in children. The findings from this research will be used to inform practical interventions and solutions to reduce child asthma re-admissions to hospitals.

This study is evaluating the effect of the PICCsox arm cover on peripherally inserted central catheter (PICC) dislodgments in patients receiving a PICC Who is it for? You may be eligible to join this study if you are aged 18 years or above, and are booked for PICC insertion in the Radiology Department of the Royal Adelaide Hospital. You may or may not be diagnosed with cancer. Study details Participants will be randomised by chance (like flipping a coin) into two groups: one group will receive a PICCsox arm cover to wear over their PICC for six weeks. The other group will not receive anything to wear over their PICC for the intervention period but will be offered a PICCsox after the six week intervention period, if they still have a PICC in place. Participants will be telephoned and asked about whether their PICC came out early and their experiences and views of the PICCsox. Participants will be selected based on their diagnosis (haematological cancers, solid tumours, infection and those who required a PICC due to difficult venous access) as we hope to get wide range of patients. This study will help Nurses and doctors know whether they should give patients a PICCsox when they have a PICC inserted to stop it coming out and to help with daily life.

Who is this study for This study is for patients with Primary refractory and early relapsed diffuse large B cell lymphoma. Treatment 4 cycles of R-CHOP chemotherapy, cycles take place every 3 weeks. A cycle of R-CHOP consists of Rituximab 375mg/m2 Infusion through a vein on Day 1 Cyclophosphamide 750mg/m2 infusion through a vein on Day 1 Doxorubicin 50mg/m2 Infusion through a vein on Day 1 Vincristine 1.4mg/m2 (2mg max) Infusion through a vein Prednisolone 100mg/day once a day for 6 days orally with a tablet Patients will undergo a PET/CT scan if the patient is refractory they will then go on to receive 2 cycles of R-ICE A cycle of R-ICE consists of Rituximab 3752 infusion through the vein on Day 1 Etoposide 100 mg/m2, 20 mins infusion through the vein on Days 1,2 & 3 Carboplatin max 800 mg, 1hr infusion through the vein on Day 1 Ifosfamide + Mesna (each) 5000 mg/m2 infusion through the vein on Days 1, 2 & 3 or as a single 24hr infusion, the treating clinician will decide which way is best for the patient. Patients will receive another PET/CT scan prior to commencing Lymphodepleting chemotherapy. This consists of either; Cyclophosphamide 250mg/m2 Infusion through a vein on D-4, D-3, D-2 & Fludarabine 25mg/m2 Infusion through a vein D-4, D-3, D-2 OR Cyclophosphamide 250mg/m2 orally with a tablet on D-4, D-3, D-2 & Fludarabine 40mg/m2 orally with a tablet on D-4, D-3, D-2 The treating clinician will decide what is the best route of administration based on the patient, local practice and availability. They will then receive 3 infusions of CAR T cells through a vein. The first dose of CAR T cells will be on Day 0 after the Lymphodepleting chemotherapy. Three dose levels will be explored, there will be 4 weeks gap between each dosing. 1. 1x107cells/m2 2. 5 x 107/m2 3. 1x108/m2. Patients will undergo blood testing, PET/CT scans and questionnaires throughout the study. The aim of this study is to improve the health outcomes of patient diagnosed with Primary refractory and early relapsed diffuse large B cell lymphoma by administering CAR T Cells early in their treatment.

The purpose of this study is to investigate the combination and efficacy and safety of Low dose Cytarabine, Venetoclax, Midostaurin and Pracinostat in patients with acute myeloid Leukaemia (AML). Who is it for? You may be eligible for this study if you are an adult over 60 years of age who has been diagnosed with AML, with no previous chemotherapy treatment. Study details Participants in this study will receive the following treatments: Depending on which Part of the trial is open for recruitment, patients eligible after screening will be registered to either 1. Part 1 - The dose finding Run-in phase or 2. Part 2 - The randomised phase 2 study The Run-Phase patients will receive either: LDAC (Low dose cytarabine) + venetoclax + midostaurin or LDAC (Low dose cytarabine) + venetoclax + pracinostat The Randomised Phase patients will receive: 1. LDAC + venetoclax (Tablets) + midostaurin (Tablets) a. LDAC 20mg/m2 subcutaneously daily D1-10 of each cycle. b. Venetoclax (Tablets) RP2D (ramp up in cycle 1 only) c. Midostaurin (Tablets) RP2D or 2. LDAC + venetoclax + pracinostat a. LDAC 20mg/m2 subcutaneously daily D1-10 of each cycle. b. Venetoclax (Tablets)RP2D (ramp up in cycle 1 only) c. Pracinostat (Tablets) RP2D or 3. LDAC + venetoclax a. LDAC 20mg/m2 subcutaneously daily D1-10 of each cycle. b. Venetoclax 600mg (Tablets)D1-28 (ramp up in cycle 1 only) All participants will undertake blood tests, bone marrow biopsies and questionnaires. This study aims to establish whether the combination of treatments, can control the disease more effectively for a longer duration.

In order to prolong peritoneal dialysis [PD] technique survival, clinicians not only need to focus on protecting patient’s residual kidney function and peritoneal membrane integrity, they also need to address the impact of PD on patient’s daily living. One potential solution is the use of incremental PD (5 days a week dialysis). We have designed an investigator-initiated study to answer the following questions: Is incremental PD a feasible dialysis prescription? • Can PD patients be safely maintained on incremental PD • How long does incremental PD last, until needing daily PD By having regular peritoneal membrane resting, does incremental PD • Maintain residual renal function and urine output? • Improve patient’s life participation? • Better preserve peritoneal membrane function? The study will recruit adult patients who have commenced peritoneal dialysis in the previous 3 months and has been designed to fit in with PD patients' standard of care so minimal additional pathology testing will be required. We expect the incremental dialysis group to report better quality of life and demonstrate non-inferiority in terms of safety data and peritonitis rates.

The purpose of this study is to assess the feasibility of collecting data on cognition over the course of treatment and recovery in patients with newly diagnosed aggressive lymphoma Who is it for? You may be eligible for this study if you are an adult who has been newly diagnosed with aggressive lymphoma, that is undergoing treatment at Austin Health. Study details All participants in this study will complete their usual treatment as prescribed by their doctor. Participants in this study will be assessed at three timepoints over the course of their treatment and recovery – one before treatment starts, one halfway, and one at the end of the treatment period. The assessment session will involve some tests to assess cognitive function and, in those participants willing to participate, a MRI brain scan and/or a PET/CT brain scan. It is hoped that this research will help determine if a larger study looking at cognitive function during chemotherapy for lymphoma is possible, adding to an underexplored area of cancer research.

The aim of this study is to assess the feasibility of a future substantive randomised controlled trial comparing the efficacy of an internet delivered interventions for rotator cuff related pain delivered via three methods. The three trial arms are; (i) usual care basic advice (about rotator cuff related pain and activity modification); (ii) the combination of online printable pamphlet and video, plus a "virtual physiotherapist" whereby participants enter their exercise and symptoms into the website and it tailors their exercise (iii) the combination of online printable pamphlet, video and "virtual physiotherapist" plus a weekly telerehabilitation session with a physiotherapist (via Zoom®).

This study aims to evaluate the need for Intravenous Fentanyl to provide Procedural analgesia during Direct Current Cardioversion for the treatment of acute onset Atrial fibrillation. Patents will be randomised to receive a pain relief medication (Fentanyl) or a placebo (Salt water) at the commencement of the procedure. All other elements of the procedure are the same. when the patient emerges and can state their name, the clinician will ask the patient to rank their perception of pain. This will be repeated at 10 minutes from the time the patient was able to state their name. The two groups will be compared to see if the patients receiving the Fentanyl rated their pain differently , to those that did not receive pain relief. This study aims to redefine and change clinical practice, avoid use of treatments when they are not indicated, improve patient safety by reducing harm from unnecessary treatments or interventions.